Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577131 | 0.90 | GABRA1 (0.35) | PDE3BPDE3ACCR2ABCB11GAA | |
| SCHEMBL5576340 | 0.89 | CCR2 (0.46) | CCR2ABCB11GAAPOLBNPSR1 | |
| SCHEMBL5576540 | 0.87 | ALDH1A1 (0.35) | CCR2ABCB11GAAPOLBNPSR1 | |
| SCHEMBL5576492 | 0.86 | MAPK8 (0.37) | MAPK8GAAPOLBNPSR1KDM4E | |
| Hydrochloric Acid SCHEMBL5577115 | 0.79 | MEN1 (0.37) | POLBKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL5577102 | 0.77 | HTR4 (0.46) | GAANPSR1KDM4EALDH1A1 | |
| SCHEMBL5239284 | 0.76 | ESR1 (0.38) | GAAPOLBNPSR1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL5577110 | 0.76 | MAPK1 (0.47) | — | |
| SCHEMBL5239288 | 0.75 | TSHR (0.36) | GAAPOLBNPSR1KDM4EALDH1A1 | |
| SCHEMBL5576641 | 0.75 | GABRA1 (0.36) | GAAPOLBNPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117840-A1 | Receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | claimed |
| EP-1604983-A1 | RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2005-12-14 | — | — | EP | claimed |
| US-20070117840-A1 | Receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-1604983-A1 | RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117840-A1 | Receptor antagonist | FSHR, NR4A1, GHRHR | PDE3B 2977/4885PDE3A 3220/4885MAPK8 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.